Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus.

Presentación del tema: "Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus."— Transcripción de la presentación:

1 Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection  J.A. Pineda, L.E. Morano-Amado, R. Granados, J. Macías, F. Téllez, M. García-Deltoro, M.J. Ríos, A. Collado, M. Delgado-Fernández, M. Suárez-Santamaría, M. Serrano, C. Miralles-Álvarez, K. Neukam J.C. Alados-Arboledas, H. Albendín, M.R. Alemán, M. del Mar Alonso, V. Asensi, M.J. Blanco, J. Borrallo, R. Cabo, Á. Camacho, M.F. Casas, Á. Castro, J. Cucurull, S. Cuéllar, F. Cuenca, I. de los Santos-Gil, C. Dueñas, E. Fernández, C. Galera, M.C. Gálvez, D. García, P. Geijo-Martínez, A. Gómez, J.L. Gómez, F. Gutiérrez, J. Hernández, J. Hernández, J. Llenas-García, M. Mancebo, M. Márquez, J.M. Martín, L. Martínez, R. Martínez-Álvarez, O. Martínez Madrid, M. del Mar Masiá, N. Merchante, D. Merino, P. Monje, R. Nuñez, M. Omar, E. Ortega, S. Padilla, C. Robledano, R. Pelazas, E. Pérez, I. Pérez-Camacho, M. Pérez-Pérez, B. Pernas, J.J. Portu, M. Raffo, L.M. Real, G. Reina, A. Rivero, A. Rivero-Juárez, A. Romero- Palacios, J. Portilla, P. Rubio, P. Ryan-Murua, P.S. de la Hoya, J. Santos, M. Serrano, C. Toyas, F. Vera-Méndez, A. Vergara, M.V. Hernández, D.V. García J.A. Pineda, L.E. Morano-Amado, R. Granados, J. Macías, F. Téllez, M. García-Deltoro, M.J. Ríos, A. Collado, M. Delgado-Fernández, M. Suárez-Santamaría, M. Serrano, C. Miralles-Álvarez, K. Neukam J.C. Alados-Arboledas, H. Albendín, M.R. Alemán, M. del Mar Alonso, V. Asensi, M.J. Blanco, J. Borrallo, R. Cabo, Á. Camacho, M.F. Casas, Á. Castro, J. Cucurull, S. Cuéllar, F. Cuenca, I. de los Santos-Gil, C. Dueñas, E. Fernández, C. Galera, M.C. Gálvez, D. García, P. Geijo-Martínez, A. Gómez, J.L. Gómez, F. Gutiérrez, J. Hernández, J. Hernández, J. Llenas-García, M. Mancebo, M. Márquez, J.M. Martín, L. Martínez, R. Martínez-Álvarez, O. Martínez Madrid, M. del Mar Masiá, N. Merchante, D. Merino, P. Monje, R. Nuñez, M. Omar, E. Ortega, S. Padilla, C. Robledano, R. Pelazas, E. Pérez, I. Pérez-Camacho, M. Pérez-Pérez, B. Pernas, J.J. Portu, M. Raffo, L.M. Real, G. Reina, A. Rivero, A. Rivero-Juárez, A. Romero-Palacios, J. Portilla, P. Rubio, P. Ryan-Murua, P.S. de la Hoya, J. Santos, M. Serrano, C. Toyas, F. Vera-Méndez, A. Vergara, M.V. Hernández, D.V. García  Clinical Microbiology and Infection  Volume 23, Issue 6, Pages 409.e5-409.e8 (June 2017) DOI: /j.cmi Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Rates of sustained virological response 12 weeks after scheduled end-of-therapy (SVR12) in an on-treatment approach and according to response at week 4 of therapy in patients with cirrhosis at baseline within the following subpopulations: (a) overall cirrhotic population; (b) HIV co-infected patients; (c) patients who concomitantly received ribavirin; (d) patients treated for 12 weeks; (e) patientts who received sofosbuvir (SOF) plus daclatasvir (DCV), with or without ribavirin (RBV); (f) patients who received SOF plus ledipasvir (LDV) plus RBV. Black bars: undetectable HCV RNA; grey bars: HCV RNA below lower limit of quantification but detectable; white bars: HCV RNA quantifiable. Black lines indicate upper 95% CI. Clinical Microbiology and Infection  , 409.e5-409.e8DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions